In France, the quality of care cannot be measured by access to new medicines
The pharmaceutical industry is calling for faster market launches for its medicines, arguing that this would prevent a supposedly lost opportunity for the French. As the Social Security financing bill is being examined in Parliament, companies are trying to shift the lines in their favor.
We haven't written up this one. Le Monde Economie has the full story — the link below goes straight to it.